Screener
Sarepta Therapeutics, Inc. SRPT Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Sarepta Therapeutics, Inc.’s reported figures.
Based on the most recent quarter.
The source filing: Sarepta Therapeutics, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335003
FAQ
- What is Sarepta Therapeutics, Inc.'s debt-to-equity?
- Sarepta Therapeutics, Inc. (SRPT) reported debt-to-equity of 0.1× in Q2 2026.
- How has Sarepta Therapeutics, Inc.'s debt-to-equity changed year-over-year?
- Sarepta Therapeutics, Inc.'s debt-to-equity decreased by 15.0% year-over-year, from 0.2× to 0.1×.
- What is the long-term trend for Sarepta Therapeutics, Inc.'s debt-to-equity?
- Over 5 years (2020 to 2025), Sarepta Therapeutics, Inc.'s debt-to-equity has grown at a 6.8% compound annual growth rate (CAGR), from 0.1× to 0.2×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Sarepta Therapeutics, Inc.'s debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude